<DOC>
	<DOCNO>NCT02053636</DOCNO>
	<brief_summary>The aim study evaluate objective response rate ( ORR ) single agent lucitanib metastatic breast cancer patient FGFR1-amplified , FGFR1-non amplify 11q amplification , FGFR1-non amplify without 11q amplification .</brief_summary>
	<brief_title>A Phase II Trial Testing Oral Administration Lucitanib Patients With Fibroblast Growth Factor Receptor ( FGFR ) 1-amplified Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Histologically confirm breast adenocarcinoma . Presence accessible metastatic lesion biopsy least one archive metastatic tumour sample . Prior firstline systemic therapy metastatic setting . Demonstrated progression disease radiological clinical assessment . Female patient , age â‰¥18 year old . Estimated life expectancy &gt; 3 month . Normal Left ventricular function Adequate haematological , hepatic renal function . For woman childbearing potential , negative pregnancy test prior initiation study drug willingness use effective contraception . Ability swallow oral capsule tablet . More two line chemotherapy without target therapy metastatic setting . Previous treatment bevacizumab within 3 month first dose Investigational Medicinal Product . Active central nervous system metastasis , cerebral oedema , and/or progressive growth . Patients impaired cardiac function . Uncontrolled arterial hypertension Patients history thrombotic disorder hereditary risk factor thromboembolic event Serum potassium level Lower Limit Normal Uncontrolled hypothyroidism . Pregnant breastfeed woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>